Tools
Stock profile

ELI LILLY & Co (LLY)

LLY · Latest close $1,382.75 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$1,382.75
As of Nov 18, 2026
Tracked funds holding
19 of 149
2026 Q2 13F filings
Opened / added
1 / 3
vs previous quarter
Trimmed / exited
13
vs previous quarter

ELI LILLY & Co (LLY) is held by 19 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions, 3 funds adding, and 13 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $7.0M sold). 2 members of Congress reported 5 purchases vs 5 sales. Latest close $1,382.75 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 2, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-7.0M
Congress
5 buys vs 5 sales
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Polen Capital Management · Saturna Capital · Alphinity Investment Management — 19 tracked funds hold LLY. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 1 sale ($7.0M). Insider trading 2 members of Congress reported buying (5 purchases vs 5 sales). Latest buy: Oct 20, 2026. Politician trading

Often held alongside

AMGEN INC (AMGN) · ISHARES RUSSELL 1000 GROWTH (IWF) · BBB FOODS INC (TBBB) · Datadog, Inc. (DDOG) · GENERAL MILLS INC (GIS) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Polen Capital Management6.89%666,912TRIMMED (-27.1%) Q3 filed Nov 13
Saturna Capital6.58%460,411TRIMMED (-17.1%) Q3 filed Nov 16
Alphinity Investment Management6.02%301,331NEW Q3 filed Nov 2
DJE Kapital5.76%246,220TRIMMED (-4.5%) Q3 filed Nov 12
OrbiMed Advisors5.73%257,900ADDED (+8.9%) Q3 filed Nov 16
Edgewood Management4.81%388,627TRIMMED (-44.0%) Q3 filed Nov 12
Mirova US4.57%354,043TRIMMED (-3.9%) Q3 filed Nov 5
Jensen Investment Management4.47%153,735TRIMMED (-33.4%) Q3 filed Nov 10
Mairs & Power Funds3.54%322,129TRIMMED (-1.3%) Q3 filed Nov 16
Winslow Capital Management2.86%693,624TRIMMED (-8.4%) Q3 filed Nov 12

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +18.8% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

1,443.50592.942024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

212024Q3: 17 funds2024Q4: 19 funds2025Q1: 19 funds2025Q2: 21 funds2025Q3: 18 funds2026Q1: 18 funds2026Q2: 19 funds2024Q32026Q2

Tracked funds holding this stock, by quarter (2024Q3–2026Q2, 7 quarters). Source: quarterly BEST lists from 13F filings — tracked funds only, not all filers. A stock appears here only if it ever made a quarterly BEST list.

All institutions · Form 13F

Institutions holding4,631 of 8,857 filers
Long-only filers among them4,618
Change vs 2026 Q1+310 net · 2,209 entered · 1,899 exited
Shares reported, all filers781,924,285
Reported value, all filers$942.1B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNYSE
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY2025$65.2B
Net income · FY2025$20.6B
Total assets · FY2025$112.5B
Shares outstanding940,745,031
Market cap (at latest close)$1,300.8B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Oct 26, 2026.

Short interest

Shares short · Oct 15, 20266,960,837
Share of shares outstanding0.74%
Days to cover3.04

Shares short at recent settlements — Jul 31, 2026: 9.1M · Aug 14, 2026: 6.6M · Aug 31, 2026: 7.9M · Sep 15, 2026: 7.5M · Sep 30, 2026: 7.0M · Oct 15, 2026: 7.0M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Oct 26, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 3K · Aug 31, 2026: 85 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Oct 26, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 1 sale by 1 insider ($7.0M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 2, 2026Hakim AnatEVP, GC & SecretarySell5,000$1,402.52$7.0MSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Oct 7, 2026LILLY ENDOWMENT, INC.Shareholder300,000$347.2MOct 7, 2026SEC filing
Aug 17, 2026Patrik JonssonOfficer6,500$7.6MAug 17, 2026SEC filing
Aug 10, 2026DONALD ZAKROWSKIOfficer2,000$2.4MAug 10, 2026SEC filing
Aug 7, 2026Hakim AnatOfficer10,000$11.9MAug 7, 2026SEC filing
Jul 7, 2026LILLY ENDOWMENT, INC.Shareholder310,000$372.0MJul 7, 2026SEC filing
Jun 26, 2026LILLY ENDOWMENT, INC.Shareholder305,000$343.9MJun 26, 2026SEC filing
Jun 10, 2026Yuffa IlyaOfficer2,500$2.9MJun 10, 2026SEC filing
May 28, 2026LILLY ENDOWMENT, INC.Shareholder310,000$335.7MMay 28, 2026SEC filing
May 22, 2026LILLY ENDOWMENT, INC.Shareholder300,000$312.5MMay 22, 2026SEC filing
May 20, 2026LILLY ENDOWMENT, INC.Shareholder305,000$311.5MMay 20, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Jul 23, 2026LILLY ENDOWMENT, INC.SC 13G/A90,376,9789.6%Jun 30, 2026SEC filing
May 1, 2026Vanguard Capital ManagementSC 13G61,295,6056.5%Mar 31, 2026SEC filing
Apr 20, 2026LILLY ENDOWMENT, INC.SC 13G/A91,896,9789.7%Mar 31, 2026SEC filing
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Jan 23, 2026LILLY ENDOWMENT, INC.SC 13G/A92,190,5169.8%Dec 31, 2025SEC filing
Oct 30, 2025LILLY ENDOWMENT, INC.SC 13G/A95,492,99310.1%Sep 30, 2025SEC filing
Oct 30, 2025The Vanguard GroupSC 13G/A80,952,5958.6%Sep 30, 2025SEC filing
Apr 16, 2025LILLY ENDOWMENT INCSC 13G/A96,016,97810.1%Mar 31, 2025SEC filing
Feb 7, 2025THE PNC FINANCIAL SERVICES GROUP, INC.SC 13G/A51,153,8375.4%Dec 31, 2024SEC filing
Jan 27, 2025LILLY ENDOWMENT INCSC 13G/A96,891,97810.2%Dec 31, 2024SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

2 members of Congress reported buying (5 purchases vs 5 sales). Bought by Democrats and Republicans. Latest buy: Oct 20, 2026.

Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.

Recent activity by member

MemberChamberPartyBuysSellsLatestAmount range
Taylor, David J.HouseR02Nov 3, 2026$1,001 - $15,000
Cisneros, GilbertHouseD30Oct 20, 2026$1,001 - $15,000
Newhouse, DanHouseR01Jul 10, 2026$1,001 - $15,000
Rulli, MichaelHouseR01Jul 1, 2026$1,001 - $15,000
Fletcher, ElizabethHouseD01Apr 8, 2026$1,001 - $15,000
Donalds, ByronHouseR20Apr 2, 2026$1,001 - $15,000

Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

Member who traded this stockSits on
Rulli, MichaelHouse Committee on Energy and Commerce
Fletcher, ElizabethHouse Committee on Energy and Commerce

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 1,181 Lobbying Disclosure Act filings named this company as client, 1999–2026; most common issues: Health Issues (733), Medicare/Medicaid (510), Trade (domestic/foreign) (318).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Politicians

· Bought by Members — Last 6 months: bought by a member of the U.S. Congress

· Bought by Both Parties — Last 6 months: bought by both Democratic and Republican members

Financial Screens

· Buffett — Companies with high ROE sustained for more than a decade

· Growth — Revenue up every year for 5 straight years

· Graham — Sound finances and a long run of profits

· Dividend Growth — Dividends raised for more than 10 years

· O'Neil CAN SLIM — Explosive earnings growth leaders

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· 52-Week High — Recently printed a new 52-week high

· Top Relative Strength — Top 20% of the universe by 6-month return

Key figures

· Buffett — Latest ROE: 74.2% · Years ROE ≥15% (of 10): 9 · 10-yr avg ROE: 72.0% · Latest net income: $10.6B

· Growth — Latest revenue: $65.2B · 5-yr revenue CAGR: 21.6% · Straight growth years: 8

· Graham — Current ratio: 1.58 · Straight profitable years: 8 · Debt ratio: — · Latest net income: $20.6B

· Dividend Growth — Dividend per share: 6.23 · Dividend yield: 0.4% · Straight dividend years: 14 · 10-yr dividend growth: 203.9%

· O'Neil CAN SLIM — 3-yr EPS growth: 49.3% · ROE: 74.2% · Latest revenue growth: 44.7%

· Bought by Members — Members buying: 2 · Buy txns: 5 · Sell txns: 5 · Latest buy: Oct 20, 2026

· Bought by Both Parties — Members buying: 2 · Buy txns: 5 · Sell txns: 5 · Latest buy: Oct 20, 2026

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Super-investor 13F BEST — appeared in 7 of the last 40 quarterly lists; latest 2026 Q2, ranked #44 of 50.

· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2025 Q3, ranked #5 of 50.

· Politician BEST — appeared in 12 of the last 20 quarterly lists; latest 2026 Q2, ranked #15 of 50.

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Heavy accumulation — 3+ tracked funds increased together757.1%+7.9%+3.6%+4.3%
Heavy exit — 3+ tracked funds sold out together1100.0%+1.6%+2.9%-1.3%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold LLY — ranked by lift, the co-holding pattern described in Methodology: AMGEN INC (AMGN) · ISHARES RUSSELL 1000 GROWTH (IWF) · BBB FOODS INC (TBBB) · Datadog, Inc. (DDOG) · GENERAL MILLS INC (GIS) · ISHARES RUSSELL 2000 ETF (IWM) · VANGUARD MRNGSTAR GR ETF-SUI (VUG) · GILEAD SCIENCES, INC. (GILD).

Filings audit: every filing lens on ELI LILLY & Co (LLY), scored — GetCoattail Research.

Recent 8-K filings

FiledItemsSource
Oct 29, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Aug 5, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
May 20, 20268.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

AMGEN INC (AMGN) · Filings audit: every filing lens on ELI LILLY & Co (LLY), scored · Practice timing on LLY

One email a week: the week’s new filings and research. Subscribe free

← LKQ  ·  LLYVA →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.